Patient exposure and disposition
| PexaVec/ durvalumab (N=16) | PexaVec/ tremelimumab/ durvalumab (N=18) | |
| Not continuing treatment, n (%) | 16 (100) | 18 (100) |
| Disease progression | 14 (88) | 12 (67) |
| Study-drug toxicity | 0 (0) | 4 (22) |
| Death | 1 (6.3) | 1 (5.6) |
| Other* | 1 (6.3)* | 1 (6)† |
| Doses of PexaVec | ||
| 1 | 0 (0) | 1 (5.6) |
| 2 | 2 (12.5) | 4 (22.2) |
| 3 | 0 (0) | 4 (22.2) |
| 4 | 14 (87.5) | 9 (50.0) |
| Median follow-up (range), months | 26.3 (1.1–26.3) | 14 (1.1–18.8) |
| Median duration of therapy (95% CI), months | 1.9 (0.8–2.9) | 1.0 (0.8–1.2) |
*Non-compliance.
†Consent withdrawal.